Practical Fragments

This blog is meant to allow Fragment-based Drug Design Practitioners to get together and discuss NON-CONFIDENTIAL issues regarding fragments.

Showing posts with label BioLeap. Show all posts
Showing posts with label BioLeap. Show all posts
10 September 2009

BioLeap leaps into collaborations

›
Pennsylvania-based BioLeap , which uses computational FBDD, has just signed a deal with GlaxoSmithKline to work on “difficult” targets. The...
›
Home
View web version
Powered by Blogger.